Novartis Shares Rise on Positive Results for Multiple Sclerosis Pill
Novartis shares rose 6.5% to $162.01 after the drugmaker reported positive results from two late-stage trials of its new multiple sclerosis pill, with patients experiencing fewer flare-ups. Options activity totaled about 13,000 contracts, 2.9 times the usual daily volume, with puts dominating trading.